Dosing and uses of Lastacaft (alcaftadine ophthalmic)
Adult dosage forms and strengths
ophthalmic solution
- 0.25%
Allergic Conjunctivitis
Indicated for prevention of itching associated with allergic conjunctivitis
Instill 1 gtt to each eye daily
Pediatric dosage forms and strengths
ophthalmic solution
- 0.25%
Allergic Conjunctivitis
Indicated for prevention of itching associated with allergic conjunctivitis
<2 years: Safety and efficacy not established
≥2 years: As adults, instill 1 gtt to each eye daily
Lastacaft (alcaftadine ophthalmic) adverse (side) effects
1-10%
Ocular
- Irritation
- Burning
- Stinging
- Redness
- Pruritus
- Eye discharge
- Eye swelling
- Erythema of eyelid
- Eyelid edema
Nonocular
- Nasopharyngitis
- Headache
- Influenza
- Somnolence
Postmarketing reports
Lacrimation increased
Vision blurred
Hypersensitivity reactions including swelling of the face or allergic dermatitis
Warnings
Contraindications
Hypersensitivity
Cautions
To minimize eye injury and contamination of dropper tip and solution, care should be taken not to touch eyelids or surrounding areas with dropper tip of bottle; keep bottle tightly closed when not in use
Keep bottle tightly closed when not in use
Do not use for contact lens–related irritation
Remove contact lenses before instillation
Pregnancy and lactation
Pregnancy category: B
Lactation: Unknown whether distributed in breast milk, caution advised
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Lastacaft (alcaftadine ophthalmic)
Mechanism of action
H1-receptor antagonist; inhibits histamine release from mast cells, decreases chemotaxis, and inhibits eosinophil activation
Pharmacokinetics
Absorption: MinimaL
Half-Life: 2 hr
Peak Plasma Time: 0.25 hr; active metabolite 1 hr
Peak Plasma Concentration: 60 pg/mL (levels fell below limit of quantification by 3 hr); active metabolite 3 ng/mL
Protein Bound: 39.2%; active metabolite 62.7%
Metabolism: Non-CYP450 cytosolic enzymes to active metabolite carboxylic acid
Administration
Instructions
If more than 1 topical ophthalmic medicinal product is being used, each one should be administered at least 5 minutes apart
